Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease

References

• Sarnak MJ, Levey AS, Schoolwerth AC, Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154–69.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262–72.
   PubMed Web of Science ®Google Scholar
• Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14:S315–20.
   PubMed Web of Science ®Google Scholar
• Vekic J, Zeljkovic A, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Spasojevic Kalimanovska V, Simic-Ogrizovic S, Dopsaj V, Spasic S. Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized high-density lipoprotein particles. Clin Biochem 2011; 44:635–41.
   PubMed Web of Science ®Google Scholar
• Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Damjanovic T, Suvakov S, Matic M, Savic-Radojevic A, Simic T, Spasojevic-Kalimanovska V, Gojkovic T, Spasic S, Dimkovic N. Association of glutathione-S-transferase gene polymorphism and lipoprotein subclasses in hemodialysis patients. Clin Biochem 2014;47:398–403.
   PubMed Web of Science ®Google Scholar
• Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Peco-Antic A, Kostic M, Vasic D, Spasic S. Characteristics of low-density and high-density lipoprotein subclasses in pediatric renal transplant recipients. Transpl Int 2011;24:1094–102.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small dense LDL. J Lipid Res 2003;44:2193–201.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, Yoshino G. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004;24:558–63.
   PubMed Web of Science ®Google Scholar
• Berneis KK, Krauss RM. Metabolic origin and clinical significance of LDL heterogeneity. J Lipid Res 2002;43: 1363–79.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525–32.
   PubMed Web of Science ®Google Scholar
• Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008;28:433–40.
   PubMed Web of Science ®Google Scholar
• Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001;280:1183–8.
   PubMed Web of Science ®Google Scholar
• Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Pricci F, Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29:831–6.
   PubMed Web of Science ®Google Scholar
• Dumic J, Dabelic S, Flögel M. Galectin-3. An open-ended story. Biochim Biophys Acta 2006;1760:616–35.
   PubMed Web of Science ®Google Scholar
• Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Memon L, Spasic S. Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size. Atherosclerosis 2009;207: 496–501.
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111–5.
   PubMed Web of Science ®Google Scholar
• Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004;24:46–53.
   PubMed Web of Science ®Google Scholar
• Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN. LDL and HDL subclass distribution in patients with end-stage renal diseases. Clin Biochem 2002;35:211–6.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size?Int J Cardiol 2006;107:166–70.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome – the heart of the matter. Nephrol Dial Transplant 2002;17(Suppl. 11):28–31.
   PubMedGoogle Scholar
• Yeo Y, Byun SW, Lee JY, Min WK, Park JS, Kim SB. Lack of association between small dense low-density lipoprotein levels and coronary artery disease in chronic hemodialysis patients. Am J Nephrol 2009;30:310–4.
   PubMed Web of Science ®Google Scholar
• Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998;152:1199–208.
   PubMed Web of Science ®Google Scholar
• MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013;23:654–63.
   PubMed Web of Science ®Google Scholar
• Gruson D, Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?Clin Biochem 2012;45:719–26.
   PubMed Web of Science ®Google Scholar
• Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Mazzitelli G, Cordone S, Pesce C, Pugliese F, Pricci F, Pugliese G. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J Pathol 2009;218:360–9.
   PubMed Web of Science ®Google Scholar
• Kim K, Mayer EP, Nachtigal M. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta 2003;1641:13–23.
   PubMed Web of Science ®Google Scholar